Stock GLTO GALECTO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Galecto, Inc.

Equities

GLTO

US36322Q1076

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 02:00:00 27/04/2024 am IST 		5-day change 1st Jan Change
0.7048 USD +5.37% Intraday chart for Galecto, Inc. +3.42% -2.11%
08/03 Galecto, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Galecto Shares Climb After Bone Marrow Disease Treatment Trial Yields Positive Results MT

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 316 76.54 29.42 19.52 19.11 - -
Enterprise Value (EV) 1 152.4 13.98 -3.368 19.52 1.009 -52.59 -90.19
P/E ratio -1.64 x -1.48 x -0.47 x -0.5 x -0.59 x -0.39 x -0.34 x
Yield - - - - - - -
Capitalization / Revenue - - - - - - -
EV / Revenue - - - - - - -
EV / EBITDA -45,57,111 x -2,69,964 x 55,467 x - - - -
EV / FCF -39,90,022 x -2,66,135 x 78,089 x - - - -
FCF Yield -0% -0% 0% - - - -
Price to Book 1.91 x 0.65 x 0.47 x - - - -
Nbr of stocks (in thousands) 25,261 25,262 25,581 27,113 27,113 - -
Reference price 2 12.51 3.030 1.150 0.7200 0.7048 0.7048 0.7048
Announcement Date 29/03/21 17/02/22 09/03/23 08/03/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - - - -
EBITDA - -33.45 -51.79 -60.72 - - - -
EBIT 1 -38.97 -33.64 -52.23 -61.21 -39.9 -34.01 -74.72 -85.7
Operating Margin - - - - - - - -
Earnings before Tax (EBT) 1 - -34.84 -51.75 -61.62 -38.35 -33.67 -74.72 -85.7
Net income 1 - -34.84 -51.75 -61.62 -38.35 -32.68 -52.41 -65.65
Net margin - - - - - - - -
EPS 2 -420.7 -7.620 -2.050 -2.430 -1.440 -1.203 -1.815 -2.075
Free Cash Flow - -38.2 -52.53 -43.13 - - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 02/09/20 29/03/21 17/02/22 09/03/23 08/03/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - - - - - -
EBITDA - - - - - -13.36 - - - - - - - -
EBIT -12.94 -13.47 - -17.12 -13.62 -13.52 -13.49 -11.16 -5.855 -6.671 - - - -
Operating Margin - - - - - - - - - - - - - -
Earnings before Tax (EBT) -12.7 -13.41 - - - - -12.99 -10.74 -8.136 -6.475 - - - -
Net income 1 -12.7 -13.41 -16.94 -16.89 -13.73 -14.07 -12.99 -10.74 -8.136 -6.475 -11.3 -10.5 -4.8 -4.3
Net margin - - - - - - - - - - - - - -
EPS 2 -0.5000 -0.5300 -0.6700 -0.6700 -0.5400 -0.5500 -0.5100 -0.4100 -0.3000 -0.2300 -0.2900 -0.2500 -0.1350 -0.1150
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 04/11/21 17/02/22 29/04/22 29/07/22 08/11/22 09/03/23 28/04/23 31/07/23 06/11/23 08/03/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - -
Net Cash position 1 164 62.6 32.8 - 18.1 71.7 109
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow -38.2 -52.5 -43.1 - - - -
ROE (net income / shareholders' equity) -73.9% -36.6% -68.9% - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share 6.550 4.640 2.430 - - - -
Cash Flow per Share -8.350 -2.070 -1.690 - - - -
Capex - 0.22 0.2 - - - -
Capex / Sales - - - - - - -
Announcement Date 29/03/21 17/02/22 09/03/23 08/03/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
0.7048 USD
Average target price
6 USD
Spread / Average Target
+751.31%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
GALECTO, INC. Stock Galecto, Inc.
-2.11% 19.11M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. GLTO Stock
  4. Financials Galecto, Inc.